Phase IIB Trial of Oral Midostaurin (PKC412), the FMS-Like Tyrosine Kinase 3 Receptor (FLT3) and Multi-Targeted Kinase Inhibitor, in Patients With Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome With Either Wild-Type or Mutated FLT3

PURPOSE: Mutations leading to constitutive activation of the FMS-like tyrosine kinase 3 receptor (FLT3) occur in blasts of 30% of patients with acute myeloid leukemia (AML). Midostaurin (PKC412; N-benzoylstaurosporin) is a multitargeted tyrosine kinase inhibitor, with demonstrated activity in patien...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Fischer, Thomas, Stone, Richard M., DeAngelo, Daniel J., Galinsky, Ilene, Estey, Elihu, Lanza, Carlo, Fox, Edward, Ehninger, Gerhard, Feldman, Eric J., Schiller, Gary J., Klimek, Virginia M., Nimer, Stephen D., Gilliland, D. Gary, Dutreix, Catherine, Huntsman-Labed, Alice, Virkus, Jodi, Giles, Francis J.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Clinical Oncology 2010
Assuntos:
ORIGINAL REPORTS
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4135183/
https://ncbi.nlm.nih.gov/pubmed/20733134
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2010.28.9678
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados